Clinical Trial

Applying Artificial Intelligence to the 12 Lead ECG for the Diagnosis of Pulmonary Hypertension: an Observational Study

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated October 5, 2023 (before its estimated August 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to apply Artificial Intelligence (AI) and machine learning technology to the resting 12-lead electrocardiogram (ECG) and assess whether it can assist doctors in the early diagnosis of Pulmonary Hypertension (PH). Early and accurate diagnosis is an important step for patients with PH. It helps provide effective treatments early which improve prognosis and quality of life. The main questions our study aims to answer are: 1. Can AI technology in the 12-lead ECG accurately predict the presence of PH? 2. Can AI technology in the 12-lead ECG identify specific sub-types of PH? 3. Can AI technology in the 12-lead ECG predict mortality in patients with PH? In this study, the investigators will recruit 12-lead ECGs from consenting participants who have undergone Right heart Catheterisation (RHC) as part of their routine clinical care. AI technology will be applied to these ECGs to assess whether automated technology can predict the presence of PH and it's associated sub-types.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-07-04.
Trial Details
NCT Number NCT05942859
Lead Sponsor Royal United Hospitals Bath NHS Foundation Trust
Collaborators: Liverpool John Moores University
Conditions Pulmonary Hypertension (Diagnosis)
Enrollment 600 participants
Start Date 2023-10
Primary Completion 2024-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2023-10-05